Cargando…

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy

Mutations in the hotspot ligand-binding domain of the estrogen receptor (ER) gene ESR1 have recently been recognized as mechanisms of endocrine resistance in endocrine receptor-positive metastatic breast cancer (MBC). Accumulating data suggest these mutations develop under the selective pressure of...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Santo, Irene, McCartney, Amelia, Migliaccio, Ilenia, Di Leo, Angelo, Malorni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966519/ https://www.ncbi.nlm.nih.gov/pubmed/31795152 http://dx.doi.org/10.3390/cancers11121894

Ejemplares similares

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
por: Malorni, Luca, et al.
Publicado: (2016)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
por: Di Donato, Samantha, et al.
Publicado: (2021)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment
por: Dessources, Kimberly, et al.
Publicado: (2022)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
por: Galardi, Francesca, et al.
Publicado: (2020)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
por: Barua, David, et al.
Publicado: (2020)

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
por: Drouyer, Aurélien, et al.
Publicado: (2023)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data
por: Romagnoli, Dario, et al.
Publicado: (2018)

ESR Statement on the Validation of Imaging Biomarkers
Publicado: (2020)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ESR1 mutations in breast cancer
por: Clatot, Florian, et al.
Publicado: (2017)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

ESR statement on the stepwise development of imaging biomarkers
Publicado: (2013)

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
por: Kuang, Yanan, et al.
Publicado: (2018)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

ESR1 mutations: Pièce de résistance
por: Button, Berry, et al.
Publicado: (2016)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
por: Turner, Natalie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_msvi6lj3mcs8ebrjqaraao7itb